Leukocare

Munchen, Germany Founded: 2003 • Age: 23 yrs
Proprietary stabilizing solutions for biologics formulations are developed.

About Leukocare

Leukocare is a Healthcare company based in Munchen (Germany) founded in 2003. Proprietary stabilizing solutions for biologics formulations are developed. Leukocare has raised $17.5 million across 2 funding rounds from investors including Petrichor and LifeCare Partners. The company has 70 employees. Leukocare offers products and services including Formulation Development, Data Science Services, Stability Studies, and Particle Characterization. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Its legal entity is LEUKOCARE AG.

Company details

Leukocare offers a proprietary formulation platform for the development of biologics. Their proprietary Stabilising and Protecting Solutions (SPS) platform offers technologies for increasing the stability and protection of therapeutic proteins in dry and liquid formulations. The platform mainly includes three major functionalities namely thermal stabilization, sterilization protection (for terminal sterilization and dry formulation of biologics) and device functionalization (for medical devices). The platform can be used mainly for the development of therapeutic antibodies, biosimilars, vaccines and medical devices. The company recently entered into a strategic alliance with Rentschler Biotechnologie, a Germany-based CDMO through which Leukocare would become its specialized technology partner and exclusive formulation developer.

  • Headquarters Munchen, Germany
  • Employees 70
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website leukocare.com
  • Social LinkedIn X
  • Legal Name Leukocare Ag
Key Metrics
  • Total Equity Funding
    $17.5M (USD)

    in 2 rounds

  • Latest Funding Round
    $17.5M (USD), Series B

    Jun 2021

  • Investors
    Petrichor

    & 1 more

  • Employee Count
    70

Products & Services of Leukocare

Leukocare offers a comprehensive portfolio of products and services, including Formulation Development, Data Science Services, Stability Studies, and Particle Characterization.

Formulation Development
Drug Product Service

Optimizes formulations for biopharmaceuticals to enhance stability and efficacy.

Data Science Services
Analytical Services

Applies AI and bioinformatics for drug development and risk reduction.

Stability Studies
Testing Services

Evaluates drug product stability under various conditions for safety.

Particle Characterization
Characterization Services

Analyzes particles in drug substances to ensure quality and manufacturability.

Funding Insights of Leukocare

Leukocare has successfully raised a total of $17.5M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $17.5 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $17.5M
  • Total Rounds 2
  • Last Round Series B β€” $17.5M
  • Investors Count 2

All 2 funding rounds of Leukocare with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2021$17.5MSeries B–Petrichor
–
Jul 2015Series A––
Valuation history

2 investors in total: 2 institutional.

Investors in Leukocare

Leukocare has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Petrichor and LifeCare Partners.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Petrichor is engaged in supporting healthcare innovation through investments.
2018petrichorcap.comNew York, USA
LifeCare Partners is involved in unspecified activities.
lifecare.partners
Premium access

Investor details for Leukocare

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Leukocare

23 people are tracked at Leukocare (10 in leadership, 11 in board & advisors, 2 in team); the tracked headcount is 70.

NameRoleGroup
Praveen Huber, Ph.D.
Vice President, Head Of Partnerships And Client Project ManagementLeadership
Georg Dönges
CFOLeadership
Dirk Winnemöller
VP, Head of CommercialLeadership
Michael Scholl
CEOLeadership
Konstadinos Salassidis
Director BD Marketing and SalesLeadership
Andreas Seidl
COOLeadership
Cornelius Pompe
VP, Head of R&DLeadership
Dr. Thea Böhm
Director Business DevelopmentLeadership
Marlen Polzer
Manager People & Organization / People PartnerLeadership
Teresa Tänzer
Head Of People & OrganizationLeadership
Bernhardt L. Trout
AdvisorBoard & advisors
Jaul-Paul Prieels
Supervisory Board MemberBoard & advisors
Wolfgang Schwandner
Supervisory Board MemberBoard & advisors
Harald Mosler
Chair of the Supervisory BoardBoard & advisors
Paul Dalby
AdvisorBoard & advisors
Ulrike Protzer
AdvisorBoard & advisors
Gerhard Ries
Supervisory Board MemberBoard & advisors
Andreas Rummelt
Supervisory Board MemberBoard & advisors
Theodore W. Randolph
AdvisorBoard & advisors
Frank Mathias
Supervisory Board MemberBoard & advisors

3 more people are available in the full profile.

Premium access

Complete people profiles for Leukocare

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Leukocare

3 dated milestones of Leukocare across 18 years, from founding to its latest funding, stage changes and deals.

  1. Founded Leukocare is founded.
  2. Funding First funding round.
  3. Funding Latest funding round, Series B, of $17.5M.

Web traffic of Leukocare

The website of Leukocare (leukocare.com) receives about 5.7K visits a month.

  • Monthly visits
    5.7K

    ▲ 73.5% vs previous month

Similar websites

Websites whose visitors overlap most with Leukocare. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
viramed.de
100%
View details
project-pharmaceutics.com
99%
View details
amicusrx.de
amicusrx.de
99%
#10,724,948–
eisbach.bio
99%
1.7K#10,492,522View details
mk2.bio
98%
View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 22 similar websites and full traffic analytics for Leukocare

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 22 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Leukocare

Premium access

Complete news archive for Leukocare

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Leukocare

Leukocare was founded in 2003 and raised its 1st funding round 12 years after it was founded.

Leukocare is headquartered in Munchen, Germany. It is registered at Munchen, Bayern, Germany.

Leukocare is a funded company, having raised a total of $17.5M across 2 funding rounds to date.

Leukocare has 70 employees.

Leukocare offers a proprietary formulation platform for the development of biologics. Their proprietary Stabilising and Protecting Solutions (SPS) platform offers technologies for increasing the stability and protection of therapeutic proteins in dry and liquid formulations. The platform mainly includes three major functionalities namely thermal stabilization, sterilization protection (for terminal sterilization and dry formulation of biologics) and device functionalization (for medical devices). The platform can be used mainly for the development of therapeutic antibodies, biosimilars, vaccines and medical devices. The company recently entered into a strategic alliance with Rentschler Biotechnologie, a Germany-based CDMO through which Leukocare would become its specialized technology partner and exclusive formulation developer.

Leukocare offers Formulation Development, Data Science Services, Stability Studies, and Particle Characterization.

Leukocare has 2 investors. Key investors include Petrichor, and LifeCare Partners.

Leukocare operates through Leukocare Ag.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available